araag2/HINT huggingface dataset:
Clinical trial NCT01319357 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Type 2 diabetes mellitus defined by fasting glucose ≥126 mg/dl or HbA1c ≥6.5% or on
             blood glucose lowering medication

          -  Age of 18 - 75 years

          -  Male and Female patients are eligible. Females of child bearing potential or within
             two years of the menopause are only eligible if pregnancy test at the screening visit
             is negative and they use adequate contraceptive precautions during the trial.

          -  The patient must demonstrate that she/he is able and willing to perform blood glucose
             measurements as necessary for Home Blood Glucose Monitoring by herself/himself after
             it was demonstrated to her/him.

        Exclusion Criteria:

          -  Any other form of diabetes mellitus than type 2 diabetes mellitus

          -  Patients with more than on one blood glucose lowering medication or on insulin therapy

          -  Last measured HbA1c > 11%

          -  Blood pressure levels ≥180/110 mmHg

          -  Body mass index >50 kg/m²

          -  Triglyceride levels >1000 mg/dl

          -  HDL-cholesterol levels <25 mg/dl

          -  Estimated creatinine clearance < 50 ml/min/1.73m²

          -  Macroalbuminuria defined by urinary albumine-to-creatinine ratio > 300 mg/g

          -  Known liver function test >3 times upper limit of normal

          -  Pregnant or breast-feeding patients

          -  Current or previous (within 6 months) treatment with an incretin-based therapy such as
             DPP 4 inhibitors and/or GLP-1 mimetics

          -  Any patient currently receiving chronic (>30 consecutive days) treatment with an oral
             corticosteroid

          -  Acute cardiovascular event (including myocardial infarction, unstable angina pectoris,
             percutaneous coronary intervention, heart failure, stroke, TIA. PRIND, intracerebral
             bleeding) <6 months prior to screening visit (visit 1)

          -  Diabetic retinopathy

          -  History of epilepsia or history of seizures

          -  Patients being treated for severe auto immune disease e.g. lupus

          -  Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             and BMS or representative staff and/or staff at the study site)

          -  Previous randomisation in the present study

          -  Participation in another clinical study within 30 days prior to visit 1

          -  Individuals at risk for poor protocol or medication compliance

          -  Subject who do not give written consent, that pseudonymous data will be transferred in
             line with the duty of documentation and the duty of notification according to § 12 and
             § 13 GCP-V
Clinical trial NCT01512004 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: propiverine hydrochloride, tolterodine extended-release tablet
SMILES: CCCOC(C(=O)OC1CCN(C)CC1)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 to 65, male or female patient has a diagnosis of overactive bladder and the
             symptoms of OAB>3 months subject has urinary frequency (average micturition frequency
             within 24h>8 times), urgency and/or urge incontinence by micturition diary card during
             screening period

          -  Mean volume of single micturition is less than 200ml by micturition diary dard during
             screening period

          -  The subject is willing and able to complete the micturition diary card correctly

          -  Subject's urine routine test show that he/she has no urinary tract infection Subject
             signs informed consent form

        Exclusion Criteria:

          -  Confirmed by the investigator that subject has severe stress incontinence.

          -  Subject who has serious heart disease or arrhythmia, in the investigator's opinion, is
             not suitable to enroll.

          -  Subject who has contraindications of anticholinergic therapy, such as urinary
             retention, gastric retention and uncontrollable angle closure glaucoma.

          -  Subject who has a symptomatic acute urinary tract infection.

          -  Subject who has a recurrent urinary tract infection.

          -  Subject who has interstitial cystitis.

          -  Subject who has an agnogenic hematuria.

          -  Subject who has a bladder outlet obstruction of clinical significance.

          -  Subject who needs retention catheterization or intermittent catheterization.

          -  Patient with malignant tumor.

          -  Subject who has received anticholinergic drugs or other drugs for treating OAB within
             washout period, or who will receive these drugs after this study begins.

          -  Subject who is pregnant or lactating, or plans to be pregnant subject who has received
             other clinical study drugs or its participating in other clinical trial within 30
             days.

          -  Women of childbearing age who has not taken sufficient contraception measures within 3
             months before random number distribution; or intends to stop the contraception
             measures during the trial or within one month after the treatment is over.
Clinical trial NCT00657241 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: carvedilol, valsartan
SMILES: COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with residual (uncontrolled) hypertension on lisinopril monotherapy, defined
             as 24-hour ambulatory diastolic BP >85 mmHg.

        Exclusion Criteria:

        A subject meeting any of the following conditions will be excluded from the study:

          -  History of serious adverse effects with ACE inhibitor, Coreg, or valsartan

          -  Known or suspected causes of secondary hypertension (e.g., renovascular stenosis,
             primary hyperaldosteronism)

          -  Known ischemic heart disease requiring beta-blocker therapy (includes angina, prior
             transmural myocardial infarction, coronary artery bypass graft surgery or percutaneous
             transluminal coronary angioplasty or stenting within 6 months prior to study entry).

          -  Heart failure (NYHA Functional Class II-IV)

          -  Obstructive valvular heart disease or obstructive hypertrophic cardiomyopathy

          -  Presence of clinically significant ventricular or supraventricular arrhythmias (e.g.
             atrial fibrillation/flutter), pre-excitation syndrome, second or third degree AV
             block, other conduction defects necessitating the implantation of a permanent cardiac
             pacemaker, or sick sinus syndrome.

          -  Chronic kidney disease (serum creatinine >2.5 within past 6 months)

          -  Uncontrolled diabetes mellitus (i.e., a fasting blood glucose >200 mg/dL [>11.1
             mmol/L] or hemoglobin A1c > 10%

          -  History of alcohol or other drug abuse within 6 months prior to enrollment

          -  Concomitant treatment or probable need for treatment with prohibited medications.
             NSAIDs, diabetes medications and other chronic meds are permitted if continued
             throughout study without dosage change.

          -  Any other medical condition which renders the subject unable to complete the study or
             which would interfere with optimal participation in the study or produce a significant
             risk to the subject

          -  Those with persistent systolic BP elevations above 179 mmHg will be discontinued from
             the study as will those with any significant adverse effect of medication.

          -  Positive pregnancy test or failure to practice adequate contraception in women of
             child-bearing potential

          -  Bronchospastic asthma requiring chronic steroid or inhaler therapy

          -  Any women with child-bearing potential
Clinical trial NCT00646321 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol (symbicort), budesonide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 6 and maximally 15 years of age

          -  Diagnosis of asthma and baseline lung function tests as determined by the protocol

          -  Has required and received treatment with inhaled corticosteroids within the timeframe
             and doses specified in the protocol

        Exclusion Criteria:

          -  Severe asthma

          -  Has required treatment with any non-inhaled corticosteroids within previous 4 weeks,
             has sensitivity to drugs specified in the protocol or requires treatment with
             beta-blockers
Clinical trial NCT00105508 (phase 3, status: completed)
Conditions: parkinson's disease, dyskinesia
ICD codes: G20, K22.4, G24.01
Drugs: sarizotan, placebo
SMILES: FC1=CC=C(C=C1)C1=CN=CC(CNC[C@H]2CCC3=CC=CC=C3O2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The subject is an out-patient.

          -  The subject presents with a diagnosis of idiopathic Parkinson's disease.

          -  Prior therapy with all registered Parkinsonian medication is allowed.

        Exclusion Criteria:

          -  (For female subjects) The subject is pregnant or lactating.

          -  The subject is participating in another clinical study or has done so within the past
             30 days.

          -  The subject has received neurosurgical intervention related to PD.

          -  The subject has relevant renal impairment.

          -  The subject has relevant hepatic impairment.

          -  The subject is suffering from any dementia or psychiatric illness.

          -  The subject has a history of allergic asthma.
Clinical trial NCT01676220 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: hoe901-u300 (new formulation of insulin glargine), lantus (insulin glargine)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

          -  Adult participants with type 2 diabetes mellitus inadequately controlled with
             non-insulin antihyperglycemic drug(s);

          -  Signed written informed consent.

        Exclusion criteria:

          -  HbA1c less than (<) 7.0% (< 53 millimole per mole [mmol/mol]) or greater than (>) 11%
             (> 97 mmol/mol)

          -  History of type 2 diabetes mellitus for less than 1 year before screening

          -  Less than 6 months before screening with non-insulin antihyperglycemic treatment

          -  Change in dose of non-insulin antihyperglycemic treatment in the last 3 month before
             screening

          -  Initiation of new glucose-lowering medications and/or weight loss drug in the last 3
             months before screening visit and/or initiation of Glucagon-like peptide-1 (GLP-1)
             receptor agonist in the last 6 months before screening visit

          -  Participants receiving only non-insulin antihyperglycemic drugs not approved for
             combination with insulin according to local labeling/local treatment guidelines and/or
             sulfonylurea or glinide (Note: non-insulin antihyperglycemic drugs not approved for
             combination with insulin, sulfonylurea and glinide are to be discontinued at baseline)

          -  Current or previous insulin use except for a maximum of 8 consecutive days (for
             example, acute illness, surgery) during the last year prior to screening

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (for example, laser, surgical
             treatment or injectable drugs) during the study period

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00260832 (phase 3, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: cytarabine or supportive care, dacogen (decitabine) only
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Must have diagnosed acute myeloid leukemia.

          2. Must have a life expectancy of at least 12 weeks.

          3. Must sign informed consent.

        Exclusion Criteria:

          1. Must not have acute promyelocytic leukemia (M3 classification)

          2. Must not have any other active systemic malignancies.

          3. Must not have inaspirable bone marrow.

          4. Must not have received previous chemotherapy (except hydroxyurea) for any myeloid
             disorder.

          5. Must not have chronic respiratory disease that requires continuous oxygen use.

          6. Must not have received any experimental drug within 4 weeks before randomization.

          7. Must not be a candidate for a bone marrow or stem cell transplant within 12 weeks
             after randomization.

          8. Must not have known HIV.
Clinical trial NCT00675688 (phase 3, status: completed)
Conditions: endometrial hyperplasia, osteoporosis
ICD codes: N85.00, N85.01, M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: bazedoxifene/conjugate estrogens (ce), raloxifene, placebo
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy, postmenopausal women aged 40 - 75 years inclusive

          -  Intact uterus

          -  Last natural menstrual cycle (without exogenous hormone therapy) completed at least 12
             consecutive months before screening

        Exclusion Criteria:

          -  A history or active presence of thrombophlebitis, thrombosis or thromboembolic
             disorders

          -  A history or active presence of cerebrovascular accident, stroke, or transient
             ischemic attack

          -  A history or active presence of malignancy, or treatment for malignancy, within the
             previous 10 years

        Additional criteria applies.
Clinical trial NCT00333125 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: travoprost 40 mcg/ml + timolol 5 mg/ml eye drops, solution (duotrav), dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops, solution (cosopt)
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 or older.

          -  Diagnosis of glaucoma or ocular hypertension.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Under 18.

          -  Other protocol-defined exclusion criteria may apply.
Clinical trial NCT01604850 (phase 3, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sof, rbv, placebo to match sof, placebo to match rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection with HCV genotype 2 or 3

          -  Had cirrhosis determination

          -  Prior treatment failure

          -  Screening laboratory values within defined thresholds

          -  Subject had not been treated with any investigational drug or device within 30 days of
             the screening visit

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein
             (NS)5B polymerase

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  History of clinically significant illness or any other major medical disorder that may
             have interfered with subject treatment, assessment or compliance with the protocol

          -  Excessive alcohol ingestion or significant drug abuse
Clinical trial NCT00362635 (phase 3, status: completed)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: clevudine
SMILES: CC1=CN([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patient is between 18 and 60, inclusive.

          2. Patient is HBV DNA positive with DNA levels at screening >= 3 x 1,000,000 copies/mL.

          3. Patient is documented to be HBsAg positive for > 6 months and HBeAg positive.

          4. Patient has AST and ALT levels which are >= 1 times and <= 10 times the upper limit of
             normal (x ULN).

          5. Patient has bilirubin levels <= 1.5 x ULN or bilirubin levels > 1.5 x ULN with
             diagnosis of Gilbert's disease and conjugated bilirubin within normal limits.

          6. Women of childbearing age must have a negative urine (b-HCG) pregnancy test before
             start of trial treatment.

          7. Patient is able to give written informed consent prior to study start and to comply
             with the study requirements.

        Exclusion Criteria:

          1. Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.

          2. Patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any
             other investigational nucleoside for HBV infection.

          3. Previous treatment with interferon must have ended at least 6 months prior to the
             screening visit.

          4. Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.

          5. Patient is co-infected with HCV or HIV.

          6. Patient has evidence of decompensated cirrhosis or hepatocellular carcinoma (alpha
             fetoprotein).

          7. Patient is pregnant or breast-feeding.

          8. Patient is unwilling to use an "effective" method of contraception during the study
             and for up to 3 months after the use of study drug ceases. For males, condoms should
             be used. Females must be surgically sterile (via hysterectomy or bilateral tubal
             ligation), post-menopausal, or using at least a medically acceptable barrier method of
             contraception (i.e., IUD, barrier methods with spermicide or abstinence).

          9. Patient has a clinically relevant history of abuse of alcohol or drugs.

         10. Patient has a significant gastrointestinal, renal, hepatic (decompensated),
             bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.

         11. Subjects who are currently participating in another investigational study or has been
             taking any investigational drug within the last 4 weeks prior to Screening Visit.

         12. Subjects who are taking any traditional Chinese medication, or has been taking any
             traditional Chinese medication within the last 2 weeks prior to Screening Visit.

         13. Any criteria, which, in the opinion of the investigator, suggests that the subject
             would not be compliant with the study protocol.
Clinical trial NCT00690820 (phase 3, status: completed)
Conditions: cystic fibrosis, pancreatic exocrine insufficiency
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, K86.81
Drugs: pancrelipase delayed release, placebo comparator
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed CF diagnosis by two positive chloride sweat tests or gene analysis

          -  Confirmed PEI by historical Coefficient of fat Absorption < 70% without
             supplementation or current or historical fecal elastase < 50µg/stool (within the last
             12 months)

          -  Currently receiving treatment with a commercially available pancreatic enzyme product
             on a stable dose for more than 3 months

          -  Clinically stable condition without evidence of acute respiratory disease or any other
             acute condition

          -  Stable body weight and agrees to abstain from sexual activity

        Exclusion Criteria:

          -  Ileus or acute abdomen

          -  History of fibrosing colonopathy, celiac disease, gastrectomy, Crohn´s disease and
             small bowel surgery other than minor resection due to meconium ileus without resulting
             in malabsorption syndrome

          -  History of distal ileal obstruction syndrome within 6 months of enrollment

          -  Use of an immunosuppressive drug

          -  Any type of malignancy involving the digestive tract in the last 5 years

          -  Known infection with HIV
Clinical trial NCT00239785 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: fty720
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Eligibility criteria:

        Inclusion Criteria

          -  Male and female patients of any race between 18 to 65 years old (inclusive)

          -  Patients scheduled to undergo a primary cadaveric or primary non-HLA identical living
             donor kidney transplantation

          -  Patients who gave written informed consent to participate in the study Exclusion
             Criteria

          -  Recipients of multi-organ transplantation or foreseen to receive a non-renal allograft
             during the study period

          -  Graft cold ischemia time greater than 40 hours.

          -  Patients with pulse rate < 50 beats per minute (bpm) at screening Other
             protocol-defined exclusion criteria may apply
Clinical trial NCT00673920 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, ocrelizumab, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    based on analysis of results and consideration of available treatments, the overall benefit to
    risk profile of ocrelizumab was not favorable in ra.
  
Eligibility criteria:

        Inclusion criteria:

          -  Adult patients, ≥ 18 years of age

          -  Active rheumatoid arthritis

          -  Inadequate treatment with any DMARD other than methotrexate

        Exclusion criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid
             arthritis

          -  Concurrent treatment with any DMARD other than methotrexate

          -  Previous treatment with any cell-depleting therapies

          -  Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline